Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Gets FDA Clearance for MammaPrint on Agilent Systems

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia has received another clearance for the firm's MammaPrint breast cancer recurrence assay.

The new clearance is for running the test on two additional Agilent microarray scanners and two Agilent Bioanalyzers. Agendia said the additional clearance will expand laboratory capacity to handle the increasing number of MammaPrint, TargetPrint, and BluePrint test results.

Previously, the MammaPrint test was only allowed to be performed at Agendia's lab in Irvine, Calif. The new clearance enables the test to be run in a central laboratory and allows Agendia to also perform the test at its lab in Amsterdam, where the firm is based.

MammaPrint was the first in vitro diagnostic multivariate index assay device approved by the FDA in early 2007.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.